Synthetic Biologics, Inc. (SYN) |
1.02 0.01 (0.99%) 10-13 00:00 |
Open: | 1.02 |
High: | 1.02 |
Low: | 0.9724 |
Volume: | 57,789 |
Market Cap: | 16(M) |
PE Ratio: | -8.5 |
Exchange: | American Stock Exchange |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 1.19 |
Resistance 1: | 1.02 |
Pivot price: | 0.00 |
Support 1: | 0.99 |
Support 2: | 0.97 |
52w High: | 4.55 |
52w Low: | 0.7 |
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.
EPS | 0.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | 0.0 |
Return on Equity (ttm) | 0.0 |
Tue, 20 Feb 2024
Morning Buzz: Fastenal Company (NASDAQ:FAST), Synthetic Biologics Inc (NYSEMKT:SYN), Manitowoc Company ... - Insider Financial
Wed, 12 Oct 2022
Synthetic Biologics Rebrands as Theriva Biologics - Yahoo Finance
Fri, 15 Jul 2022
Synthetic Biologics Announces Reverse Stock Split - GlobeNewswire
Tue, 10 May 2022
Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple ... - GlobeNewswire
Wed, 09 Feb 2022
Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference - PR Newswire
Tue, 24 Nov 2020
Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American - BioSpace
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |